Effector Therapeutics: Clinical Trials

12 trials sponsored by Effector Therapeutics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 terminated, 2 unknown. 9 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Terminated 4, Completed 3, Unknown 2
Phase 16Terminated 3, Completed 2, Unknown 1

Follow Effector Therapeutics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biospecimen Collection, Tomivosertib - Acute Myeloid Leukemia
Phase 1TerminatedNorthwestern University82023-09-292026-06-11
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Alpelisib, Tamoxifen, Zotatifin - Breast Cancer, HER2-negative Breast Cancer
Phase 2CompletedJennifer Lee Caswell-Jin192023-03-202026-02-12
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
Zotatifin, Placebo - Corona Virus Infection
Phase 1CompletedEffector Therapeutics362021-07-012023-10-05
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Tomivosertib, Pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer
Phase 2UnknownEffector Therapeutics682021-06-022024-04-30
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
tomivosertib, paclitaxel - Breast Cancer
Phase 1CompletedTranslational Research in Oncology192020-08-252022-07-20
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
eFT226, Sotorasib, Fulvestrant - Solid Tumor, Adult
Phase 1 / Phase 2UnknownEffector Therapeutics302019-10-252024-05-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
eFT508 - Castrate-resistant Prostate Cancer (CRPC)
Phase 2TerminatedEffector Therapeutics162018-11-272024-06-21
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Tomivosertib (eFT-508) - Solid Tumors
Phase 2CompletedEffector Therapeutics392018-07-252023-03-22
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
eFT508 - Triple Negative Breast Cancer, Hepatocellular Carcinoma
Phase 2TerminatedEffector Therapeutics32017-11-212019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
eFT508, Avelumab - Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Phase 2CompletedEffector Therapeutics562017-09-182019-07-18
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Tomivosertib (eFT-508) - Lymphoma
Phase 1 / Phase 2TerminatedEffector Therapeutics282017-02-082020-11-02
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
eFT508 - Cancer
Phase 1 / Phase 2TerminatedEffector Therapeutics662015-12-032020-11-02

Conditions studied

Breast Neoplasms (2)  ·  COVID-19 (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Coronavirus Infections (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Thyroid Diseases (1)  ·  Triple Negative Breast Neoplasms (1)

Interventions

tomivosertib (9)  ·  Fulvestrant (2)  ·  Alpelisib (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  Specimen Handling (1)  ·  Tamoxifen (1)  ·  Trastuzumab (1)  ·  abemaciclib (1)  ·  avelumab (1)  ·  pembrolizumab (1)  ·  sotorasib (1)

Countries

United States (11)  ·  Australia (1)  ·  Canada (1)  ·  Georgia (1)

Top investigators

Jeremy Barton, MD (4)  ·  Douglas Warner, MD (3)  ·  Jennifer Caswell-Jin (1)  ·  Lyon Gleich, MD (1)  ·  Lyon Gliech, MD (1)  ·  Michael Pollak, MD (1)  ·  Shira N Dinner (1)

Results publications

PMID 34187739, PMID 37694854

NIH funding

P30CA060553 (1)